Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamideShannon R. McCurdy, Yvette L. Kasamon, Douglas E. Gladstone et al.|Blood|2015Cited by 299
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamideShannon R. McCurdy, Leo Luznik, Yvette L. Kasamon et al.|Haematologica|2016Cited by 187
Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trialJavier Bolaños‐Meade, Robert A. Brodsky, Kenneth R. Cooke et al.|The Lancet Haematology|2019Cited by 154
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamideAmy E. DeZern, Robert A. Brodsky, Marianna Zahurak et al.|Blood Advances|2020Cited by 149
Absence of Post-Transplantation Lymphoproliferative Disorder after Allogeneic Blood or Marrow Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease ProphylaxisJennifer A. Kanakry, Richard F. Ambinder, Yvette L. Kasamon et al.|Biology of Blood and Marrow Transplantation|2013Cited by 114